1. Universidad Estatal de Bolívar
  2. Producción Científica - UEB
  3. INVESTIGACIÓN
  4. Producción Científica
Por favor, use este identificador para citar o enlazar este ítem: https://dspace.ueb.edu.ec/handle/123456789/5994
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorMarofi, Faroogh-
dc.contributor.authorSulaiman Rahman, Heshu-
dc.contributor.authorThangavelu, Lakshmi-
dc.contributor.authorDorofeev, Aleksey-
dc.contributor.authorBayas Morejón, Favian-
dc.contributor.authorShirafkan, Naghmeh-
dc.contributor.authorShomali, Navid-
dc.contributor.authorStanley Chartrand, Max-
dc.contributor.authorJarahian, Mostafa-
dc.contributor.authorVahedi, Ghasem-
dc.contributor.authorMohammed, Rebar-
dc.contributor.authorShahrokh, Somayeh-
dc.contributor.authorAkbari, Morteza-
dc.contributor.authorMotavalli Khiavi, Farhad-
dc.date.accessioned2023-10-27T14:56:06Z-
dc.date.available2023-10-27T14:56:06Z-
dc.date.issued2021-03-22-
dc.identifier.citationMarofi, F., Rahman, H. S., Thangavelu, L., Dorofeev, A., Bayas-Morejón, F., Shirafkan, N., Shomali, N., Chartrand, M. S., Jarahian, M., Vahedi, G., Mohammed, R. N., Shahrokh, S., Akbari, M., & Khiavi, F. M. (2021). Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. Stem Cell Research & Therapy 2021 12:1, 12(1), 1–21. https://doi.org/10.1186/S13287-021-02251-7es_MX
dc.identifier.issn1757-6512-
dc.identifier.urihttps://dspace.ueb.edu.ec/handle/123456789/5994-
dc.descriptionhttps://stemcellres.biomedcentral.com/articles/10.1186/s13287-021-02251-7es_MX
dc.description.abstractIn recent decades, a new method of cellular immunotherapy was introduced based on engineering and empowering the immune effector cells. In this type of immunotherapy, the immune effector cells are equipped with chimeric antigen receptor (CAR) to specifically target cancer cells. In much of the trials and experiments, CAR-modified T cell immunotherapy has achieved very promising therapeutic results in the treatment of some types of cancers and infectious diseases. However, there are also some considerable drawbacks in the clinical application of CAR-T cells although much effort is in progress to rectify the issues. In some conditions, CAR-T cells initiate over-activated and strong immune responses, therefore, causing unexpected side-effects such as systemic cytokine toxicity (i.e., cytokine release syndrome), neurotoxicity, on-target, off-tumor toxicity, and graft-versus-host disease (GvHD). To overcome these limitations in CAR-T cell immunotherapy, NK cells as an alternative source of immune effector cells have been utilized for CAR-engineering. Natural killer cells are key players of the innate immune system that can destroy virus-infected cells, tumor cells, or other aberrant cells with their efficient recognizing capability. Compared to T cells, CAR-transduced NK cells (CAR-NK) have several advantages, such as safety in clinical use, non-MHC-restricted recognition of tumor cells, and renewable and easy cell sources for their preparation. In this review, we will discuss the recent preclinical and clinical studies, different sources of NK cells, transduction methods, possible limitations and challenges, and clinical considerations.es_MX
dc.language.isoenges_MX
dc.publisherUniversidad Estatal de Bolívares_MX
dc.relation.ispartofseriesPCM-UEB;21-003-
dc.rightsinfo:eu-repo/semantics/openAccesses_MX
dc.subjectCARes_MX
dc.subjectNK CELLSes_MX
dc.subjectT CELLSes_MX
dc.subjectIMMUNOTHERAPYes_MX
dc.titleRenaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapyes_MX
dc.typearticlees_MX
Aparece en las colecciones: Producción Científica

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
PCM-21-003- MAROFI FAROOGH, Renaissance of armored.pdfISSN: 1757-65121,41 MBAdobe PDFVisualizar/Abrir
Mostrar el registro sencillo del ítem


Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.